Back to results
US 2009/0156555 A1Published application
Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
AssigneeBristol-Myers Squibb Company
InventorsChunjian Liu, Katerina Leftheris, Vivekananda M. Vrudhula, James Lin
Life of this patent
Estimating the term…
Abstract
Compounds having the Formula (I), including pharmaceutically acceptable salts thereof wherein at least one of X1, X2 or X3 is and any remaining X1, X2 or X3 is hydrogen, which are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, A1, A2 and m are as described herein.
Claims23
A compound of Formula I:
- or pharmaceutically acceptable salts thereof, wherein
- at least one of X1, X2 or X3 is
- and any remaining X1, X2 or X3 is hydrogen;
- A1 and A2 are each independently selected from optionally-substituted alkyl, optionally-substituted cycloalkyl, optionally-substituted aryl, optionally-substituted aralkyl, optionally-substituted heterocyclo and optionally-substituted heteroaryl;
- R1, R3 and R5 are each independently selected from hydrogen, optionally-substituted alkyl, —OR14, —C(═O)NR14R14a, —NR14R14a, —SO2NR14R14a, —NR14SO2NR14aR14b, —NR14aSO2R14, —NR14C(═O)R14a, —NR14CO2R14a, —NR14C(═O)NR14aR14b, halogen, cyano, optionally-substituted cycloalkyl, optionally-substituted aryl, optionally-substituted heterocyclo and optionally-substituted heteroaryl;
- R2 is independently selected from hydrogen and optionally-substituted alkyl;
- R4 is independently selected from:
- R6 is attached to any available carbon atom of the phenyl ring and at each occurrence is independently selected from optionally-substituted alkyl, halogen, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, alkanoyl, alkanoyloxy, thiol, alkylthio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, arylsulfonylamine, alkylsulfonylamine, sulfonic acid, alkysulfonyl, sulfonamido, phenyl, benzyl, aryloxy and benzyloxy, wherein each R6 group in turn may be further substituted by one to two R18;
- R14, R14a and R14b are independently selected from hydrogen, optionally-substituted alkyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclo, and optionally-substituted heteroaryl, except when R14 is joined to a sulfonyl group, as in —S(═O)R14, —SO2R14, and —NR14aSO2R14, then R14 is not hydrogen;
- R18 is independently selected from C1-6alkyl, C2-6alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, amino, C1-4alkylamino, aminoC1-4alkyl, hydroxy, hydroxyC1-4alkyl, alkoxy, C1-4alkylthio, aryl, heterocyclo, (aryl)alkyl, aryloxy, and (aryl)alkoxy;
- R27 and R28 are independently selected from hydrogen, optionally-substituted alkyl, optionally-substituted cycloalkyl, optionally-substituted aryl, optionally-substituted aralkyl, optionally-substituted heterocyclo and optionally-substituted heteroaryl;
- one of D, E, G, J or L is ═N— and each remaining D, E, G, J or L is ═C—;
- m is 0, 1, 2 or 3;
- n is 0 or 1;
- and
- k is 0, 1 or 2.
13 more elements
A compound having the Formula II:
- or pharmaceutically acceptable salts thereof, wherein
- R7 is independently selected from:
- R8 and R9 are independently selected from optionally-substituted alkyl, optionally-substituted cycloalkyl, optionally-substituted aryl, optionally-substituted aralkyl, optionally-substituted heterocyclo and optionally-substituted heteroaryl, or R8 and R9 can be taken together to be optionally substituted lactam;
- and
- n is 0 or 1.
2 more elements
Dependencies are inferred from the claim text.